Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | PTPRC | P08575 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29368452 | 0.89 | CYP1A2 (0.47) | GSK3BCYP1A2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL260864 | 0.89 | CYP1A2 (0.47) | GSK3BCYP1A2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL10884758 | 0.84 | CYP1A2 (0.60) | GSK3BCYP1A2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL19336225 | 0.84 | POLB (0.52) | GSK3BCYP1A2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL25287818 | 0.83 | GSK3B (0.45) | GSK3BCYP1A2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL13006522 | 0.82 | CYP1A2 (0.42) | GSK3BCYP1A2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL38665418 | 0.82 | CYP1A2 (0.46) | GSK3BCYP1A2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL16975488 | 0.81 | ALDH1A1 (0.58) | GSK3BCYP1A2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL6596247 | 0.81 | ALDH1A1 (0.56) | GSK3BCYP1A2TDP1ALDH1A1CYP3A4 | |
| SCHEMBL12982928 | 0.81 | ALDH1A1 (0.49) | GSK3BCYP1A2TDP1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7189864-B2 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2007-03-13 | — | — | US | disclosed |
| US-6974876-B2 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-12-13 | — | — | US | disclosed |
| US-20050171366-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2005-08-04 | — | — | US | disclosed |
| US-20030225285-A1 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. | 2003-12-04 | — | — | US | disclosed |
| EP-0970066-B1 | Preparation of aminoepoxides from aminoaldehydes and an in situ formed halomethyl organometallic reagent | SEARLE & CO (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6570027-B2 | Forming a diastereoselective epoxide from a chiral alpha-amino aldehyde | G. D. SEARLE & CO. | 2003-05-27 | — | — | US | disclosed |
| US-20020161234-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 2002-10-31 | — | — | US | disclosed |
| US-6388094-B1 | FORMING AN AMINOEPOXIDE | G.D. SEARLE & CO. | 2002-05-14 | — | — | US | disclosed |
| EP-0855388-B1 | Method for making intermediates useful in synthesis of retroviral protease inhibitors | SEARLE & CO (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6127556-A | Epoxide formation by continuous in-situ synthesis process | G. D. SEARLE & CO. (US) | 2000-10-03 | — | — | US | disclosed |
| WO-1998029401-A1 | AMINOEPOXIDES FROM AMINOALDEHYDES AND IN-SITU FORMED HALOMETHYL ORGANOMETALLIC REAGENT | G.D. SEARLE & CO. (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5648511-A | Method for making intermediates useful in the synthesis of retroviral protease inhibitors | G.D. SEARLE & CO. (US) | 1997-07-15 | — | — | US | disclosed |
| US-5583238-A | Method for making intermediates useful in synthesis of retroviral protease inhibitors | G. D. SEARLE & CO. (US) | 1996-12-10 | — | — | US | disclosed |
| EP-0730570-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1996-09-11 | — | — | EP | disclosed |
| EP-0641333-B1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | SEARLE & CO (US) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995014653-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1995-06-01 | — | — | WO | disclosed |
| EP-0641333-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS. | SEARLE & CO (US) | 1995-03-08 | — | — | EP | disclosed |
| US-5395827-A | Analgesic, anticonvulsant, antiepileptic and anxiolytic agents | GUILFORD PHARMACEUTICALS INC. (US) | 1995-03-07 | — | — | US | disclosed |
| WO-1993023388-A1 | METHOD FOR MAKING INTERMEDIATES USEFUL IN SYNTHESIS OF RETROVIRAL PROTEASE INHIBITORS | G.D. SEARLE & CO. (US) | 1993-11-25 | — | — | WO | disclosed |
| WO-1993005772-A1 | φ-[2-(PHOSPHONOALKYL)PHENYL]-2-AMINOALKANOIC ACIDS AS ANTAGONISTS OF EXCITATORY AMINO ACID RECEPTORS | NOVA PHARMACEUTICAL CORPORATION (US) | 1993-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020161234-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | GSK3B 2132/4885CYP1A2 622/4885TDP1 1562/4885 |
| US-20030225285-A1 | Method for preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | GSK3B 2243/4885CYP1A2 656/4885TDP1 1558/4885 |
| US-20050171366-A1 | Method of preparing intermediates useful in synthesis of retroviral protease inhibitors | PREP, DNPEP, ANPEP | GSK3B 2132/4885CYP1A2 622/4885TDP1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.